Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

By R. Dworkin, D. Turk, K. Wyrwich, D. Beaton, C. Cleeland, John T. Farrar, J. Haythornthwaite, Mark Jensen, R. Kerns, D. Ader and 30 more. Journal of Pain, 2008

3,237 citations recorded by the source corpus.

Subfields: Anesthesiology and Pain Medicine, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/cf43c677d73395f9a0b26824fdcad28319e5be42

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Anesthesiology and Pain Medicine

1. N. Finnerup
2. T. S. Jensen
3. S. Sindrup
4. Clifford J. Woolf

In Pharmacology

1. D. Turk
2. D.walaa badawy
3. T. S. Jensen
4. K. Kroenke
5. S. Sindrup
6. N. Finnerup
7. K. Thorlund
8. B. Löwe

In Physiology

1. N. Finnerup
2. T. S. Jensen
3. S. Sindrup
4. Clifford J. Woolf
5. Henrik Kehlet
6. F. Perkins

Citations in the corpus

• Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. (2014, methodology): “…delivered by dental hygienists who were trained and supervised by clinical psychologists were found efficacious compared with usual TMD care (S. F. Dworkin et al., 2002) and compared with continuous oral contraceptive therapy (used to reduce hormonal fluctuations associated with TMD pain in…”
• GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. (2013, background): “This result would be of limited use without knowledge of the MID, and thus the comment includes the estimated MID (10 units [30]), suggesting a modest effect (row (B) in Table 4).”
• Development and initial validation of an expanded and revised version of the Short‐form McGill Pain Questionnaire (SF‐MPQ‐2) (2009, background): “Considered together, these data suggest that the SF-MPQ-2 total and subscale scores are responsive to change and that changes in these scores are meaningful to patients, both of which are considered very important criteria in the development of outcome measures for clinical trials of chronic pain tr”
• The Brief Pain Inventory User Guide (2009, methodology): “The use of these single items is supported by the IMMPACT recommendations for assessing pain in clinical trials (Dworkin et al., 2005; Turk et al., 2006; Dworkin et al., 2008) and by the FDA Draft Guidance for Industry: PatientReported Outcome Measures (Food and Drug Administration, 2006).”
• Using Anchor-Based Methods to Determine the Smallest Effect Size of Interest (2019, methodology): “A more patient-centered anchor-based approach to estimate the MID also uses a global rating about whether patients have improved or worsened, but asks the patients themselves to provide a subjective global rating of change, which is then used as an anchor (Cuijpers et al., 2014; Dworkin et al., 2008”
• Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial (2018, background): “Other 19 (16) 24 (20) Primary pain diagnosisa”
• The evidence for pharmacological treatment of neuropathic pain (2010, positive): “For that reason it has been recommended that additional outcome domains rather than anchor-based methods such as pain intensity are used to evaluate the importance of improvement or the opposite [27].”
• Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial (2013, background): “Stratification factors Neurotoxic agent Paclitaxel 44 (40) 43 (39) 87 (40)”
• Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis (2018, background): “Current systematic reviews have a number of limitations, leaving uncertainty with regard to the benefits and harms associated with opioid therapy for CNCP.”